With a 2% negative return so far, January appears to end the same way as December which also closed 2% down. But despite the consecutive negative months, it must be noted that unlike October 204, which saw a 6.2% fall, the subsequent months’ close have not been too deep in the red, pointing to the presence of buying interest.
Biocon buys back an investor stake in biologics unit, posts Rs 25 crore net profit in Q3FY25
Biocon’s board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected
January 30, 2025